TriSalus Life Sciences, Inc. TLSI
Medical Specialities · IPO 2021 · data as of November 13, 2026
TriSalus Life Sciences, Inc. (TLSI) is a healthcare company listed in the US with a market value of about $150M. In the twelve months to September 30, 2026 it had revenue of $46M and net income of -$26M, a net margin of -56.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -4266%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 91% below the current price.
About TriSalus Life Sciences
TriSalus Life Sciences is listed in the US and classified in medical specialities, IPO year 2021. Revenue went from $12M in 2022 to $45M in 2025, growth of about 53.9% a year. It was profitable in 1 of the last 5 years in our data. Its share count rose by 12141% over three years (dilution for shareholders). It spends 33% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $46M | $45M | $29M | $19M | $12M | — |
| Net income | -$26M | -$39M | -$30M | -$59M | -$47M | $5M |
| Free cash flow | -$25M | -$19M | -$41M | -$51M | -$33M | — |
| EPS (diluted) | $-0.40 | $-1.84 | $-1.31 | $-6.77 | $-161.55 | — |
| Net margin | -56.6% | -86.9% | -102.1% | -320.7% | -380.6% | — |
| ROIC | — | -4266.0% | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is TriSalus Life Sciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 91% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does TriSalus Life Sciences pay a dividend?
Not currently.
Is TriSalus Life Sciences a good stock to buy?
We do not give buy or sell advice. TriSalus Life Sciences scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.